SCHEMBL20559166

SCHEMBL20559166

O=C(O)C1CC1c1ncc2ccccn12

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 11/20 0.44
▸ ALDH1A1 P00352 11/20 0.44
▸ MAPT P10636 6/20 0.44
▸ CHEK1 O14757 1/20 0.44
▸ LIMK1 P53667 1/20 0.44
▸ MAPK14 Q16539 1/20 0.44
▸ TDP1 Q9NUW8 1/20 0.44
▸ NR4A2 P43354 2/20 0.41
▸ RXRA P19793 1/20 0.41
▸ RXRB P28702 1/20 0.41
▸ RXRG P48443 1/20 0.41
▸ HPGD P15428 6/20 0.40
▸ FFAR1 O14842 1/20 0.40
▸ RAB9A P51151 5/20 0.39
▸ MEN1 O00255 5/20 0.39
▸ KMT2A Q03164 5/20 0.39
▸ NPC1 O15118 2/20 0.39
▸ SMN1; SMN2 Q16637 2/20 0.39
▸ HSD17B10 Q99714 3/20 0.37
▸ GLA P06280 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31215203 0.80 L3MBTL1 (0.41) KDM4EALDH1A1MAPTCHEK1LIMK1
SCHEMBL29802624 0.71 ALDH1A1 (0.46) KDM4EALDH1A1MAPTHPGDRAB9A
SCHEMBL16473318 0.69 KDM4E (0.53) KDM4EALDH1A1MAPTCHEK1LIMK1
SCHEMBL20558938 0.68 ALDH1A1 (0.46) ALDH1A1HPGDRAB9AMEN1KMT2A
SCHEMBL20558936 0.68 ALDH1A1 (0.46) ALDH1A1HPGDRAB9AMEN1KMT2A
SCHEMBL7376394 0.68 KDM4E (0.44) KDM4EALDH1A1MAPTCHEK1LIMK1
SCHEMBL7544996 0.68 HSD11B1 (0.44) KDM4EALDH1A1MAPTCHEK1LIMK1
SCHEMBL29391988 0.67 ALDH1A1 (0.46) KDM4EALDH1A1MAPTCHEK1LIMK1
SCHEMBL5217474 0.66 FFAR1 (0.70) ALDH1A1HPGDFFAR1SMN1; SMN2GAA
SCHEMBL8295172 0.66 FFAR1 (0.70) ALDH1A1HPGDFFAR1SMN1; SMN2GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11420944-B2 Voltage-dependent t-type calcium channel blocker NIPPON CHEMIPHAR CO., LTD. (JP) 2022-08-23 — — US disclosed
US-20190077767-A1 VOLTAGE-DEPENDENT T-TYPE CALCIUM CHANNEL BLOCKER NIPPON CHEMIPHAR CO., LTD. (JP) 2019-03-14 — — US disclosed
EP-3404021-A1 VOLTAGE-DEPENDENT T-TYPE CALCIUM CHANNEL INHIBITOR Nippon Chemiphar Co., Ltd. (JP) 2018-11-21 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11420944-B2 Voltage-dependent t-type calcium channel blocker CACNA1I, CACNA1G, CACNA1E KDM4E 1595/4885ALDH1A1 3247/4885MAPT 574/4885
US-20190077767-A1 VOLTAGE-DEPENDENT T-TYPE CALCIUM CHANNEL BLOCKER CACNA1I, CACNA1G, CACNA1E KDM4E 2036/4885ALDH1A1 3220/4885MAPT 707/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback